46 research outputs found
Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons
Successful five-item triage for the broad spectrum of mental disorders in pregnancy – a validation study
The impact of currently licensed therapies on viral and immune responses in Chronic Hepatitis B: considerations for future novel therapeutics.
Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity and mortality related to CHB, these therapies are limited in providing functional cure. The treatment paradigm in CHB is rapidly evolving with a number of new agents in the developmental pipeline. However, until novel agents with functional cure capability are available in the clinical setting, there is a pressing need to optimize currently licensed therapies. Here, we discuss current agents used alone and/or in combination strategies along with the impact of these therapies on viral and immune responses. Novel treatment strategies are outlined, and the potential role of current therapies in the employment of pipeline agents is discussedWellcome Trust Clinical Research Training Fellowship (107389/Z/15/Z)NIHR Academic Clinical LectureshipBarts Charity Project Grants (723/1795 and MGU/0406NIHR Research for patient benefit award (PB‐PG‐0614‐34087) to PTF
Persistence and dispersal in a Southern Hemisphere glaciated landscape: the phylogeography of the spotted snow skink (Niveoscincus ocellatus) in Tasmania
Why, who and when to start treatment for chronic hepatitis B infection.
Chronic hepatitis B remains a major global health challenge due to morbidity and mortality from hepatocellular carcinoma and complications of liver cirrhosis. Current treatment regimens are non-curative and, once initiated, treatment is of indefinite duration for the majority. The decision to initiate treatment decisions is based on risk stratification.
Advances in our understanding of the natural history of chronic hepatitis B have led to a paradigm shift in recommendations for treatment. Emerging non-invasive biomarkers of disease activity will further enhance disease stratification.
In this review, we summarise the guidance from major international societies on treatment for chronic hepatitis B and explore some of the novel approaches to disease assessment
Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks
The authors were supported by a Barts and The London Charity Large Project grant (723/1795
to P.T.F.K.) and an NIHR Research for patient benefit award (Grant No. PB-PG-0614-34087 to PTFK); a Singapore
Translational Research Investigator Award (NMRC/STaR/013/2012 to A.B.); institutional funding from the Fox
Chase Cancer Center (W.S.M.); and a Fox Chase Cancer Center Core Grant (CA006927) (S.L.)